This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene (CNC) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 2.31% and 1.06%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Factors to Note Ahead of Humana (HUM) Q2 Earnings Release
by Zacks Equity Research
Humana's (HUM) second-quarter results are likely to reflect higher premiums from the Retail segment and overall membership growth, partly offset by elevated technology-linked investments.
Humana (HUM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $488.97, marking a +0.67% move from the previous day.
Humana (HUM) Stock Moves -0.63%: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $484.46, marking a -0.63% move from the previous day.
Strength Seen in Humana (HUM): Can Its 3.2% Jump Turn into More Strength?
by Zacks Equity Research
Humana (HUM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Centene (CNC) Wins Contract to Serve Delaware's Medicaid Members
by Zacks Equity Research
Centene's (CNC) Delaware subsidiary receives a contract from the State of Delaware's DHSS to efficiently serve the diversified health needs of the state's Medicaid members.
Zacks Investment Ideas feature highlights: Humana
by Zacks Equity Research
Humana is part of Zacks Investment Ideas article.
This Health Care Giant is Breaking Out to New All-Time Highs
by Bryan Hayes
The formation of a market bottom typically starts with accumulation in certain industry groups and sectors.
HUM or CNC: Which Stock is Better-Positioned at the Moment?
by Zacks Equity Research
Humana (HUM) and Centene (CNC) are poised to grow in the promising HMO space. We try to find out which one fares better via comparative evaluation.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Humana (HUM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $487.03, marking a +0.76% move from the previous day.
Humana (HUM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $472.92 in the latest trading session, marking a -1.26% move from the prior day.
Acadia Healthcare (ACHC) JV to Build Behavioral Health Hospital
by Zacks Equity Research
Acadia Healthcare (ACHC) enters into a JV with Massachusetts-based Tufts Medicine to construct a behavioral health hospital and address the dire need for better behavioral healthcare services across Boston.
Humana (HUM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $468.33, moving +1.33% from the previous trading session.
Humana Inc. (HUM) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Humana (HUM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Humana (HUM) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Catalyst Biosciences, Inc. (CBIO) and Humana (HUM) have performed compared to their sector so far this year.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $454.64 in the latest trading session, marking a +1.47% move from the prior day.
Why You Should Retain Humana (HUM) in Your Portfolio Now
by Zacks Equity Research
Humana's (HUM) strategic acquisitions help it boost its footprint and expand the product portfolio.
Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTCS
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $428.44, marking a +1.24% move from the previous day.
Humana (HUM) Unveils Transition of Units to CenterWell Brand
by Zacks Equity Research
Humana (HUM) announces the rebranding of its pharmacy divisions to the CenterWell brand, reflecting the rapid expansion initiatives to grow the brand and better serve members.
Humana (HUM) to Offer Home Care Model to Virginia's MA Members
by Zacks Equity Research
Humana (HUM) expands the customer reach of its unit's value-based home care model to Virginia, with an aim to offer better in-home care services to the state's Medicare Advantage members.
Humana (HUM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $450.52, marking a +0.16% move from the previous day.
Zacks Industry Outlook Highlights UnitedHealth Group Anthem, Humana, Centene, and Select Medical
by Zacks Equity Research
UnitedHealth Group, Anthem, Humana, Centene, and Select Medical are part of Zacks Industry Outlook article.